Platelet-Rich Plasma (PRP) vs. Platelet-Derived Growth Factor (PDGF): Why Precise Wound Care Terminology Matters
- a few seconds ago
- 11 min read
Imagine a patient with type 2 diabetes mellitus battling a chronic, exuding, non-healing foot ulcer for 30+ days. The patient's wound care team? Has done everything right. Conscientious offloading. Diligent dressing changes. Targeting the underlying infection. The wound simply refuses to progress in a healing trajectory.
This patient? Has become the textbook candidate for autologous PRP therapy.
All of the boxes are checked off. Appropriate wound? Check. Inside Medicare's coverage window? Check. The right autologous preparation? Check. Yet, the claim could come back denied over a single acronym.
That acronym? "PDGF."
PRP is the autologous preparation a wound team draws, concentrates, and applies to a chronic wound. And it isn't a single molecule — it's a cocktail. Spin down a patient's own blood, and the platelets you concentrate carry a whole roster of growth factors in their α-granules: platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and basic fibroblast growth factor (bFGF) — each cueing a different arm of the repair cascade, from new blood-vessel formation to cell recruitment to collagen synthesis.¹,² PDGF is one ingredient in that cocktail — not the cocktail itself. Which is exactly why the confusion is so easy: PRP genuinely contains PDGF, so talk about PRP drifts naturally toward it. Scientifically, the relationship is real. Terminologically, they are not interchangeable — and to Medicare, they are not the same product.
Medicare does not read your chart clinically. It reads it against a rulebook — National Coverage Determination (NCD) 270.3 — and in that rulebook, "autologous PRP" and "autologous PDGF" are two different products with opposite coverage. One has a narrow covered lane. The other is nationally non-covered. Same patient. Same wound. Same syringe. The word that lands in the documentation can determine which side of the coverage line the claim falls on.
And it's an easy line to cross, because the loose usage isn't just a bedside habit. Medicare's own contractors write it the same way.
What Medicare’s Rulebook Actually Says
Medicare's rulebook for this treatment pathway is a single national policy: National Coverage Determination (NCD) 270.3, "Blood-Derived Products for Chronic Non-Healing Wounds."³ It sets the national baseline for coverage, and every Medicare Administrative Contractor (MAC) works from it. The policy is far narrower than many wound care teams assume.
The covered pathway is narrow. Autologous PRP is covered nationally for chronic, non-healing diabetic wounds, but only when the preparation device carries FDA clearance for managing exuding cutaneous wounds and only during the first 20 weeks of treatment.³ That's the full covered indication: one wound etiology, one preparation standard, one treatment window, and one billing code — G0465.
Now here's what the same policy places on its nationally non-covered list:
Autologous PDGF.³
Becaplermin, a non-autologous growth factor.³
PRP applied to a closed surgical incision or to a dehisced wound.³
See? The distinction is not academic. "Autologous PDGF" isn't a typo or a loose synonym for the covered product; it's a separately listed, nationally non-covered item, appearing just lines away from the PRP Medicare will cover. Same policy, opposite coverage outcome.
The policy distinguishes them by what's actually in the vial. PRP is a cellular concentrate containing white cells, red cells, plasma, platelets, fibrin, and even stem cell and fibrocyte precursors. PDGF, by contrast, "does not contain cells and was previously marketed as a product to be used by patients at home."³ One is a clinician-applied cellular preparation; the other is an acellular product assigned to a different, non-covered category. So when "PDGF" lands in a patient's chart, a reviewer doesn't read it as shorthand for "PRP" — it names something Medicare has already decided not to cover.
The policy's history sharpens the distinction — because it didn't begin as a PRP policy at all. It began as a non-coverage determination. Medicare declined to cover a home-use autologous product marketed as a “platelet-derived wound healing formula,” citing insufficient evidence of safety and efficacy.⁴,⁵ That original framing — platelet-derived, and not covered — is where this policy started. Autologous PRP only entered the frame in 2003, when CMS formally determined it was "sufficiently different from PDGF" to be judged on its own terms — distinguishing the two by the presence of cells in the preparation, its use by a clinician rather than at home, and its nature as a process rather than a product.⁶ Even then, PRP didn't gain regular national coverage for diabetic wounds until the 2021 revision. So these aren't loose synonyms with a shared past: "PDGF" is the older terminology tied to the product category the original policy addressed as non-covered; "PRP" is the newer one it eventually — and narrowly — allowed, and CMS itself drew the boundary between them. Opposite coverage histories, one document.
One final distinction: national coverage applies only to diabetic wounds. Venous ulcers, pressure ulcers, and PRP beyond 20 weeks are not expressly covered nationally, but they are not nationally prohibited either. NCD 270.3 leaves those decisions to the local contractors.³
The LCD Trap: Four Look-Alike Policies That Don't Govern Wounds
In 2003, CMS went to the trouble of formally determining that PRP and PDGF were different enough to be judged as separate products.⁶ Two decades later, MACs processing the claims have blurred the line right back — in writing.
Four active LCDs, each titled, simply, "Platelet Rich Plasma," fold the two terms together. In their own coverage language, PRP is "also referred to as autologous platelet-derived growth factors" — the exact name the NCD reserves for the non-covered product.⁷⁻¹⁰ The irony: the policies that share the treatment's name use the claim-sinking acronym as a synonym for the covered one.
The kicker? Every one of those active LCDs is a musculoskeletal policy — written to establish that PRP is investigational and non-covered for tennis elbow, arthritic knees, rotator cuffs, and plantar fasciitis.⁷⁻¹⁰ None of them governs wound care. For wounds, they do exactly one thing: point back to NCD 270.3.
We've watched this play out in real time — a capable wound care team reaches for "the LCD" to settle a wound-PRP question, without realizing the policy in front of them was written about joints. The reflex is entirely understandable. It's also precisely how the wrong document ends up steering a coverage decision.
And here is the part that decides who absorbs the risk: none of this loose language protects a provider. When a claim is adjudicated, it is measured against the NCD's named line items — the covered product and the non-covered one — not against a synonym in a contractor's summary. A MAC can call PRP "PDGF" in its own coverage criteria and still deny a claim documented as "PDGF." The looseness runs one direction. The contractors can blur the line. The chart on your desk cannot.
What Compliant PRP Documentation Looks Like
Here's the uncomfortable arithmetic. A contractor can call PRP "autologous platelet-derived growth factors" in its own coverage policy and lose nothing. A commercial payer can use the terms interchangeably in its medical policy and lose nothing. The rulebook can carry a name it has carried for decades and lose nothing. The only party in this arrangement that pays for imprecision is the one holding the chart.
That asymmetry isn't fair, but it is entirely predictable — and predictable is something a wound care program can work with. Because the terminology surrounding these products is inconsistent, the only reliable defense is to document with enough specificity that no reviewer, no matter which document they're reading from, can map the covered treatment onto a non-covered pathway.
Practically, that means the chart should never make a reviewer infer anything. NCD 270.3 names the elements it requires; the documentation should answer each of them by name, in the language the policy uses:
Name the product the way the policy names it. "Autologous platelet-rich plasma (PRP)." Not "PDGF," "platelet-derived growth factors," "growth factor therapy," "platelet gel," or "biologic." The rulebook has one name — use that one, every time, in the procedure note, the physician order, and the operative record alike.
Name the etiology. National coverage reaches one wound type: the chronic, non-healing diabetic wound. If the chart says "chronic ulcer" and leaves the reviewer to piece the diabetes together from the problem list, the chart has done half the job.
Document chronicity and failed standard care. Document that the wound has been present ≥30 days and failed to heal, despite standard wound care — offloading, debridement, moisture management, infection control, glycemic optimization. The NCD requires that standard wound care was tried and failed. The chart has to show it.
Name the device and its clearance. Coverage attaches to a preparation device whose FDA clearance includes management of exuding cutaneous wounds. The device isn't a footnote in this policy — it's a coverage criterion. Record it.
Track the clock. The covered window is the first 20 weeks. Treatment number and week of therapy belong in every note, so the 20th week never arrives as a surprise.
Bill the covered lane — and know what the neighboring lane actually is. One code carries national coverage for the diabetic wound: G0465. Its neighbor, G0460, is the non-diabetic PRP code, and CMS leaves coverage and frequency for those wounds entirely to local contractor discretion.¹¹ Billing G0460 isn't billing a covered service; it's stepping outside national coverage and asking your MAC to decide. Know which lane you're in before the claim goes out, not after.
Two diagnosis codes, not one. This is where the "name the etiology" discipline stops being philosophy and becomes a claims edit. A G0465 claim must carry both a diabetes mellitus diagnosis code and a chronic ulcer diagnosis code.¹¹ One without the other is denied outright — CARC 50, "not deemed a medical necessity," with a remark code pointing straight back at the NCD itself.¹¹ The wound and the diabetes have to be on the claim together. A chart that establishes both means nothing if the claim carries only one.
Know the 21st week. The covered window is the first 20 weeks — but week 21 isn't a wall, it's a fork. CMS leaves PRP beyond 20 weeks to local contractor discretion, and those claims must carry the -KX modifier.¹¹ File past week 20 without it, and the claim is denied for benefit maximum reached (CARC 119).¹¹ Teams that track treatment number and week of therapy in every note see that fork coming. Teams that don't, meet it as a denial.
None of this is exotic. Read it back and it's just a chart that says exactly what happened, in the words the rulebook recognizes. But that is precisely the discipline the terminology drift erodes — a clinician who has spent all week hearing "PDGF" used as a synonym for PRP will eventually write it that way, and the note will look completely normal on the screen. It will read like good medicine to the clinician writing the documentation, but to a reviewer it will simply read as the wrong product.
Two things follow from that, and they're the difference between knowing about this trap and being protected from it. The first is that terminology precision has to be screened for before treatment — while the patient is still a candidate, when a mismatch is a conversation instead of a denial. The second is that it has to be audited afterward, because the drift is invisible from the inside. The word looked right when it was written. It always does.
Screening and Auditing: Two Places to Catch a Terminology Problem
Knowing about a documentation trap and being protected from one are different things. The gap between them is process — and for terminology drift specifically, there are exactly two places to close it.
Patient Screening
Before a patient is treated, someone has to walk the coverage criteria one at a time and confirm the answer is really there: Is this wound diabetic, and does the chart say so plainly? Has it been present at least 30 days and failed standard care — with that failure documented, not assumed? Is the preparation device FDA-cleared for exuding cutaneous wounds? Where is this patient in the 20-week window? Will this bill as G0465, with both diagnosis codes on the claim? A prospective screen turns every one of those from a discovery into a decision.
Chart Auditing
After treatment, the chart has to be read the way a reviewer would read it — cold, without the benefit of knowing what was actually in the syringe. This is where terminology drift surfaces, because it is invisible from the inside. Nobody notices themselves writing "PDGF." The word looked right when it was written. A retrospective chart review is the only mechanism that reliably catches the note that reads like good medicine and names the wrong product.
SHS Insight: Shared Health Services builds both instruments for the wound care programs we partner with. Our PRP Screening Tool is the prospective front door — a pre-treatment coverage screen that walks NCD 270.3's criteria one at a time, flags the non-covered indications (autologous PDGF, becaplermin, closed surgical incisions, dehisced wounds), and confirms the covered lane before a patient is treated. Our PRP Chart Review Tool is the retrospective back door — an audit instrument that reads a completed chart against the same national standard, so a documentation gap surfaces in an internal review instead of a payer's. Both are available to our contracted partners, and we work directly with center staff on how to use them.
The point of either tool isn't paperwork. It's that terminology precision stops depending on any one clinician remembering, mid-procedure note, that the acronym everyone around them uses casually is the one Medicare treats as a different product.
The Fine Print Is Everywhere
Step back from PRP for a moment and the uncomfortable part comes into focus: this blog post covered one treatment pathway, governed by one national policy, hinging on one acronym.
Now consider all of the treatment modalities a wound center employs: cellular and tissue-based products (CTPs), hyperbaric oxygen therapy (HBOT), debridement, negative pressure wound therapy (NPWT), etc. Every one of them carries its own coverage architecture — its own criteria, its own documentation expectations, its own local contractor discretion layered on top of a national rule, its own vocabulary that means one thing in the clinic and something more specific in the policy. And every one of them has its own version of the gap between what a clinician did and what the chart says they did.
No clinician can hold all of it in their head while also taking care of patients.
What makes the difference is whether a program has a partner in place whose job is to read the fine print — to track when a national policy is revised, when a code's descriptor changes, when the vocabulary in a coverage document drifts away from the vocabulary at the bedside, and to translate all of it into something a clinical team can actually use on a day-to-day basis.
SHS Insight: This is the work Shared Health Services does alongside our partners every day. We don't take over a wound care program — we equip it. That means clinical guidance, compliance support, documentation training, and audit readiness across the full service line: wound care and hyperbaric medicine, the national policies and the local ones, the coverage criteria and HCPCS/CPT codes. Our team reads the fine print so your clinical team can stay focused on the patient in front of them. If your program is running advanced therapies without process support for catching this kind of drift, that's a conversation worth having.
A wound care team should be judged on the care it delivers. Not on whether someone reached for the wrong acronym.
(800) 474-0202 | sales@sharedhealthservices.com
References
Dos Santos RG, Santos GS, Alkass N, et al. The regenerative mechanisms of platelet-rich plasma: a review. Cytokine. 2021;144:155560. doi:10.1016/j.cyto.2021.155560
Everts PA, Lana JF, Alexander RW, et al. Profound properties of protein-rich, platelet-rich plasma matrices as novel, multi-purpose biological platforms in tissue repair, regeneration, and wound healing. Int J Mol Sci. 2024;25(14):7914. doi:10.3390/ijms25147914
Blood-Derived Products for Chronic Non-Healing Wounds. National Coverage Determination 270.3, version 6. Centers for Medicare & Medicaid Services. Effective April 13, 2021. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=217
Platelet-Derived Wound Healing Formula. National Coverage Determination 270.3, version 1. Centers for Medicare & Medicaid Services. Effective December 28, 1992. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=217&ncdver=1
Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). Centers for Medicare & Medicaid Services. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=300
Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190N). Centers for Medicare & Medicaid Services. December 15, 2003. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=95
Palmetto GBA. Platelet Rich Plasma. Local Coverage Determination L38745. Centers for Medicare & Medicaid Services. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38745
National Government Services. Platelet Rich Plasma. Local Coverage Determination L38937. Centers for Medicare & Medicaid Services. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38937
Novitas Solutions. Platelet Rich Plasma. Local Coverage Determination L39068. Centers for Medicare & Medicaid Services. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39068
First Coast Service Options. Platelet Rich Plasma. Local Coverage Determination L39071. Centers for Medicare & Medicaid Services. Accessed July 14, 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39071
National Coverage Determination (NCD) 270.3 Blood-Derived Products for Chronic, Non-Healing Wounds. Medicare Claims Processing Manual, Pub. 100-04, Transmittal 11214 (CR 12403). Centers for Medicare & Medicaid Services. January 20, 2022. Accessed July 14, 2026. https://www.cms.gov/files/document/r11214cp.pdf